(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
French high-speed train slams into truck, killing TGV driver - 2Trouvez La Carte De Cr\u00e9dit Id\u00e9ale Pour Vos Besoins En Belgique
- 3NASA, in a rare move, cuts space station mission short after an astronaut's medical issue
- 4Step by step instructions to Contrast Lab Jewels and Regular Ones
- 5Trump signs bill allowing whole milk to return to school lunches
- Steinmeier honours Italian 'guest workers' who rebuilt German economy
- Gen Z workplace stereotypes were TV’s favorite punchline in 2025
- NI economy losing momentum due to Iran crisis
- Could the Star of Bethlehem have actually been a comet?
- Central African Republic's president sworn in for a third term after disputed election
- Nestlé says 413,793 KitKat candy bars stolen en route from Italy to Poland
- 5 Morning Schedules That Stimulate Your Day
- Manual for 6 Hot Brilliant Beds
- New studies of old dogs help scientists understand where they came from
